Egypt · Delayed Price · Currency is EGP Ibnsina Pharma Statistics
Total Valuation
Ibnsina Pharma has a market cap or net worth of EGP 10.36 billion. The enterprise value is 32.84 billion.
| Market Cap | 10.36B |
| Enterprise Value | 32.84B |
Important Dates
The next estimated earnings date is Tuesday, November 11, 2025.
| Earnings Date | Nov 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Ibnsina Pharma has 1.01 billion shares outstanding.
| Current Share Class | 1.01B |
| Shares Outstanding | 1.01B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 26.01% |
| Owned by Institutions (%) | 23.67% |
| Float | 652.98M |
Valuation Ratios
The trailing PE ratio is 16.36 and the forward PE ratio is 7.87. Ibnsina Pharma's PEG ratio is 0.18.
| PE Ratio | 16.36 |
| Forward PE | 7.87 |
| PS Ratio | 0.15 |
| PB Ratio | 4.35 |
| P/TBV Ratio | 4.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | 0.18 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.94, with an EV/FCF ratio of -8.95.
| EV / Earnings | 51.86 |
| EV / Sales | 0.48 |
| EV / EBITDA | 9.94 |
| EV / EBIT | 10.85 |
| EV / FCF | -8.95 |
Financial Position
The company has a current ratio of 1.01, with a Debt / Equity ratio of 10.02.
| Current Ratio | 1.01 |
| Quick Ratio | 0.67 |
| Debt / Equity | 10.02 |
| Debt / EBITDA | 7.23 |
| Debt / FCF | -6.51 |
| Interest Coverage | 1.33 |
Financial Efficiency
Return on equity (ROE) is 38.89% and return on invested capital (ROIC) is 8.78%.
| Return on Equity (ROE) | 38.89% |
| Return on Assets (ROA) | 6.86% |
| Return on Invested Capital (ROIC) | 8.78% |
| Return on Capital Employed (ROCE) | 96.04% |
| Revenue Per Employee | 12.38M |
| Profits Per Employee | 115,134 |
| Employee Count | 5,500 |
| Asset Turnover | 2.47 |
| Inventory Turnover | 9.87 |
Taxes
In the past 12 months, Ibnsina Pharma has paid 77.41 million in taxes.
| Income Tax | 77.41M |
| Effective Tax Rate | 9.01% |
Stock Price Statistics
The stock price has increased by +168.93% in the last 52 weeks. The beta is 0.51, so Ibnsina Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.51 |
| 52-Week Price Change | +168.93% |
| 50-Day Moving Average | 10.29 |
| 200-Day Moving Average | 8.37 |
| Relative Strength Index (RSI) | 47.35 |
| Average Volume (20 Days) | 3,691,590 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ibnsina Pharma had revenue of EGP 68.07 billion and earned 633.24 million in profits. Earnings per share was 0.63.
| Revenue | 68.07B |
| Gross Profit | 5.63B |
| Operating Income | 3.03B |
| Pretax Income | 859.18M |
| Net Income | 633.24M |
| EBITDA | 3.17B |
| EBIT | 3.03B |
| Earnings Per Share (EPS) | 0.63 |
Balance Sheet
The company has 1.40 billion in cash and 23.87 billion in debt, giving a net cash position of -22.48 billion or -22.30 per share.
| Cash & Cash Equivalents | 1.40B |
| Total Debt | 23.87B |
| Net Cash | -22.48B |
| Net Cash Per Share | -22.30 |
| Equity (Book Value) | 2.38B |
| Book Value Per Share | 2.36 |
| Working Capital | 376.10M |
Cash Flow
In the last 12 months, operating cash flow was -3.40 billion and capital expenditures -272.00 million, giving a free cash flow of -3.67 billion.
| Operating Cash Flow | -3.40B |
| Capital Expenditures | -272.00M |
| Free Cash Flow | -3.67B |
| FCF Per Share | -3.64 |
Margins
Gross margin is 8.28%, with operating and profit margins of 4.45% and 1.15%.
| Gross Margin | 8.28% |
| Operating Margin | 4.45% |
| Pretax Margin | 1.26% |
| Profit Margin | 1.15% |
| EBITDA Margin | 4.66% |
| EBIT Margin | 4.45% |
| FCF Margin | n/a |
Dividends & Yields
Ibnsina Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 4.20% |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 6.11% |
| FCF Yield | -35.40% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 1, 2022. It was a forward split with a ratio of 1.16666.
| Last Split Date | Jun 1, 2022 |
| Split Type | Forward |
| Split Ratio | 1.16666 |
Scores
Ibnsina Pharma has an Altman Z-Score of 2.58 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.58 |
| Piotroski F-Score | 5 |